90
Participants
Start Date
June 30, 2003
Primary Completion Date
January 31, 2011
Study Completion Date
January 31, 2011
Cyclophosphamide (CTX)
300 mg/m\^2 by vein (IV) over 3 hours every 12 hours for 6 doses days 1, 2, 3 of
Vincristine
2 mg by vein (IV) weekly for 3: Days 1, 8, 15
Doxorubicin
50 mg/m\^2 by vein (IV) over 24 hours
Decadron
80 mg by vein (IV) or by mouth (P.O.) daily days 1-4 and 15-18
G-CSF
10 mcg/kg/day (rounded) by vein (IV) or under the skin (subcutaneously) within 72 ± 48 hours
Methotrexate (MTX)
200 mg/m2 by vein (IV) over 2 hours followed by 800 mg/m2 over 22 hours on day 1
Ara-C
3 gm/m\^2 by vein (IV) over 2 hours every 12 hours for 4 doses on days 2 and 3.
Pegaspargase
2,500 units/m2 by vein (IV) on day 1 of odd courses and day 5 of even courses
UT MD Anderson Cancer Center, Houston
Collaborators (1)
Enzon Pharmaceuticals, Inc.
INDUSTRY
M.D. Anderson Cancer Center
OTHER